KKR finalizes $2.1 billion loan to fund Integer acquisition
KKR & Co. (KKR) secured a $2.1 billion loan to finance its $5.7 billion acquisition of Integer Holdings (ITGR), with improved borrowing terms due to strong investor demand. The loan was priced at 2.5 percentage points above its benchmark, lower than initially discussed. The transaction is expected to close by the end of 2026, with Citigroup (C) leading the loan sale. KKR shares fell 1.9% on Friday, while Integer shares remained unchanged.
How this was made
The 30-second read
Why it matters
The financing terms are better than initially discussed, indicating strong investor demand for leveraged‑loan assets and reducing financing risk for the deal.
Market read
The deal underscores robust leveraged‑loan activity and adds a significant M&A transaction to the healthcare device sector.
What to watch
Potential regulatory scrutiny of large private‑equity acquisitions in the medical‑device sector.
Background
The article reports KKR's newly priced leveraged loan that will fund its acquisition of Integer Holdings, providing context on loan market trends.
Ticker impact
KKR finalized a $2.1 billion leveraged loan to fund its $5.7 billion acquisition of Integer Holdings.
Modest upside pressure on KKR as the financing is secured at favorable rates.
Deal financing is new information; market participants may view the lower spread as a positive signal for KKR's acquisition execution.
Integer Holdings is the target of KKR's $5.7 billion all‑cash acquisition, financed by the new $2.1 billion loan.
Potential short‑term upside for ITGR as the transaction closes later in 2026.
The acquisition is confirmed with financing details, providing clear catalyst for Integer's stock.
Market effects
Highlights strong demand for leveraged‑loan financing in the M&A space, supporting loan‑fund managers.
U.S. leveraged‑loan market sees increased investor appetite, potentially boosting related banking stocks.
Signals continued global appetite for large‑scale buyout financing, relevant for cross‑border private‑equity activity.
Counterpoint
If loan market liquidity tightens, the financing cost could rise, pressuring KKR's returns on the deal.
Key entities
- Private‑Equity FirmKKR & Co.
Acquirer financing the Integer purchase.
- Medical‑Device ManufacturerInteger Holdings
Target of the $5.7 billion acquisition.
- BankCitigroup
Lead underwriter for the $2.1 billion loan.
